241 related articles for article (PubMed ID: 27287035)
1. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R; Rostomyan L; Castermans E; Caberg JH; Camperos P; Krivoy J; Cuauro E; Bours V; Daly AF; Beckers A
Pituitary; 2016 Oct; 19(5):507-14. PubMed ID: 27287035
[TBL] [Abstract][Full Text] [Related]
2. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.
Rostomyan L; Daly AF; Petrossians P; Nachev E; Lila AR; Lecoq AL; Lecumberri B; Trivellin G; Salvatori R; Moraitis AG; Holdaway I; Kranenburg-van Klaveren DJ; Chiara Zatelli M; Palacios N; Nozieres C; Zacharin M; Ebeling T; Ojaniemi M; Rozhinskaya L; Verrua E; Jaffrain-Rea ML; Filipponi S; Gusakova D; Pronin V; Bertherat J; Belaya Z; Ilovayskaya I; Sahnoun-Fathallah M; Sievers C; Stalla GK; Castermans E; Caberg JH; Sorkina E; Auriemma RS; Mittal S; Kareva M; Lysy PA; Emy P; De Menis E; Choong CS; Mantovani G; Bours V; De Herder W; Brue T; Barlier A; Neggers SJ; Zacharieva S; Chanson P; Shah NS; Stratakis CA; Naves LA; Beckers A
Endocr Relat Cancer; 2015 Oct; 22(5):745-57. PubMed ID: 26187128
[TBL] [Abstract][Full Text] [Related]
3. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant.
Joshi K; Daly AF; Beckers A; Zacharin M
Horm Res Paediatr; 2018; 90(3):196-202. PubMed ID: 29953972
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
5. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
6. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
7. Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma.
Maheshwari HG; Prezant TR; Herman-Bonert V; Shahinian H; Kovacs K; Melmed S
J Clin Endocrinol Metab; 2000 Sep; 85(9):3409-16. PubMed ID: 10999842
[TBL] [Abstract][Full Text] [Related]
8. Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
Schoof E; Dörr HG; Kiess W; Lüdecke DK; Freitag E; Zindel V; Rascher W; Dötsch J
Horm Res; 2004; 61(4):184-9. PubMed ID: 14739526
[TBL] [Abstract][Full Text] [Related]
9. X-linked acrogigantism syndrome: clinical profile and therapeutic responses.
Beckers A; Lodish MB; Trivellin G; Rostomyan L; Lee M; Faucz FR; Yuan B; Choong CS; Caberg JH; Verrua E; Naves LA; Cheetham TD; Young J; Lysy PA; Petrossians P; Cotterill A; Shah NS; Metzger D; Castermans E; Ambrosio MR; Villa C; Strebkova N; Mazerkina N; Gaillard S; Barra GB; Casulari LA; Neggers SJ; Salvatori R; Jaffrain-Rea ML; Zacharin M; Santamaria BL; Zacharieva S; Lim EM; Mantovani G; Zatelli MC; Collins MT; Bonneville JF; Quezado M; Chittiboina P; Oldfield EH; Bours V; Liu P; W de Herder W; Pellegata N; Lupski JR; Daly AF; Stratakis CA
Endocr Relat Cancer; 2015 Jun; 22(3):353-67. PubMed ID: 25712922
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.
Goldenberg N; Racine MS; Thomas P; Degnan B; Chandler W; Barkan A
J Clin Endocrinol Metab; 2008 Aug; 93(8):2953-6. PubMed ID: 18492755
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy.
Frohman LA; Bonert V
Pituitary; 2007; 10(3):283-9. PubMed ID: 17534717
[TBL] [Abstract][Full Text] [Related]
12. Eight-year follow-up of a child with a GH/prolactin-secreting adenoma: efficacy of pegvisomant therapy.
Bergamaschi S; Ronchi CL; Giavoli C; Ferrante E; Verrua E; Ferrari DI; Lania A; Rusconi R; Spada A; Beck-Peccoz P
Horm Res Paediatr; 2010; 73(1):74-9. PubMed ID: 20190543
[TBL] [Abstract][Full Text] [Related]
13. GHRH excess and blockade in X-LAG syndrome.
Daly AF; Lysy PA; Desfilles C; Rostomyan L; Mohamed A; Caberg JH; Raverot V; Castermans E; Marbaix E; Maiter D; Brunelle C; Trivellin G; Stratakis CA; Bours V; Raftopoulos C; Beauloye V; Barlier A; Beckers A
Endocr Relat Cancer; 2016 Mar; 23(3):161-70. PubMed ID: 26671997
[TBL] [Abstract][Full Text] [Related]
14. Somatic GPR101 Duplication Causing X-Linked Acrogigantism (XLAG)-Diagnosis and Management.
Rodd C; Millette M; Iacovazzo D; Stiles CE; Barry S; Evanson J; Albrecht S; Caswell R; Bunce B; Jose S; Trouillas J; Roncaroli F; Sampson J; Ellard S; Korbonits M
J Clin Endocrinol Metab; 2016 May; 101(5):1927-30. PubMed ID: 26982009
[TBL] [Abstract][Full Text] [Related]
15. AIP mutations and gigantism.
Rostomyan L; Potorac I; Beckers P; Daly AF; Beckers A
Ann Endocrinol (Paris); 2017 Jun; 78(2):123-130. PubMed ID: 28483363
[TBL] [Abstract][Full Text] [Related]
16. Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child.
Dutta P; Reddy KS; Rai A; Madugundu AK; Solanki HS; Bhansali A; Radotra BD; Kumar N; Collier D; Iacovazzo D; Gupta P; Raja R; Gowda H; Pandey A; Devgun JS; Korbonits M
J Clin Endocrinol Metab; 2019 Aug; 104(8):3539-3544. PubMed ID: 31125088
[TBL] [Abstract][Full Text] [Related]
17. Pituitary gigantism: a retrospective case series.
Creo AL; Lteif AN
J Pediatr Endocrinol Metab; 2016 May; 29(5):597-602. PubMed ID: 26887033
[TBL] [Abstract][Full Text] [Related]
18. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Tajima T; Tsubaki J; Ishizu K; Jo W; Ishi N; Fujieda K
Endocr J; 2008 Jul; 55(3):595-9. PubMed ID: 18445999
[TBL] [Abstract][Full Text] [Related]
19. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
20. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
